Photoactivatable Cisplatin-Combretastatin-BODIPY Pt(IV) Prodrug for Dual-Action Light-Controlled Chemotherapy

Area of Science:

• Medicinal Chemistry
• Cancer Therapeutics
• Photodynamic Therapy

Background:

• Platinum(IV) prodrugs offer improved therapeutic potential over platinum(II) agents.
• Combretastatin A4 (CA4) is a potent tubulin polymerization inhibitor with anticancer activity.
• Developing targeted drug delivery systems is crucial for minimizing chemotherapy side effects.

Purpose of the Study:

• To design and synthesize a novel dual-action, red light-activatable platinum(IV) prodrug (BDP-Pt-CA4) for controlled release of cisplatin and CA4.
• To demonstrate light-induced, on-demand release of both chemotherapeutic agents from the prodrug.
• To investigate the intracellular drug release and its effect on cancer cells.

Main Methods:

• Synthesis and characterization of the BDP-Pt-CA4 prodrug.
• In vitro studies to assess red light-induced drug release.
• Cellular uptake and drug release studies in cancer cells.
• Single-cell low-stress scanning ion conductance microscopy (SICM) to observe drug effects.

Main Results:

• Successful design and synthesis of the dual-action BDP-Pt-CA4 prodrug.
• Demonstration of red light-triggered release of both cisplatin and CA4.
• Evidence of controllable drug release within cancer cells.
• First observation of light-induced release of a tubulin polymerization inhibitor from a photoactivatable prodrug using SICM.

Conclusions:

• BDP-Pt-CA4 represents a novel photoactive Pt(IV)-CA4 prodrug capable of dual-action chemotherapy.
• Light-controlled release of platinum and CA4 offers a promising strategy for targeted cancer treatment.
• This approach has the potential to reduce systemic toxicity and improve therapeutic outcomes.